BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 9649151)

  • 21. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
    De Ioris MA; Castellano A; Ilari I; Garganese MC; Natali G; Inserra A; De Vito R; Ravà L; De Pasquale MD; Locatelli F; Donfrancesco A; Jenkner A
    Eur J Cancer; 2011 Mar; 47(4):572-8. PubMed ID: 21112775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
    Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
    Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group.
    Donfrancesco A; De Bernardi B; Carli M; Mancini A; Nigro M; De Sio L; Casale F; Bagnulo S; Helson L; Deb G
    Eur J Cancer; 1995; 31A(4):612-5. PubMed ID: 7576980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-intensive use of cyclophosphamide in ablation of neuroblastoma.
    Kushner BH; O'Reilly RJ; LaQuaglia M; Cheung NK
    Cancer; 1990 Sep; 66(6):1095-100. PubMed ID: 2400963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
    Häberle B; Bode U; von Schweinitz D
    Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
    Brunetto AL; Castillo LA; Petrilli AS; Macedo CD; Boldrini E; Costa C; Almeida MT; Kirst D; Rodriguez-Galindo C; Pereira WV; Watanabe FM; Pizza M; Benites E; Morais V; Gadelha A; Nakasato A; Abujamra AL; Gregianin LJ;
    Pediatr Blood Cancer; 2015 Oct; 62(10):1747-53. PubMed ID: 25917418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
    Rubie H; Delattre O; Hartmann O; Combaret V; Michon J; Bénard J; Peyroulet MC; Plantaz D; Coze C; Chastagner P; Baranzelli MC; Frappaz D; Lemerle J; Sommelet D
    Eur J Cancer; 1997 Oct; 33(12):1917-22. PubMed ID: 9516824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to N7 induction chemotherapy in children more than one year of age diagnosed with metastatic neuroblastoma treated in UKCCSG centers.
    Kohler JA; Ellershaw C; Machin D;
    Pediatr Blood Cancer; 2007 Sep; 49(3):234-9. PubMed ID: 17252561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.
    Valteau-Couanet D; Michon J; Boneu A; Rodary C; Perel Y; Bergeron C; Rubie H; Coze C; Plantaz D; Bernard F; Chastagner P; Bouzy J; Hartmann O
    J Clin Oncol; 2005 Jan; 23(3):532-40. PubMed ID: 15659499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience. Société Française d'Oncologie Pédiatrique.
    Bouffet E; Baranzelli MC; Patte C; Portas M; Edan C; Chastagner P; Mechinaud-Lacroix F; Kalifa C
    Br J Cancer; 1999 Mar; 79(7-8):1199-204. PubMed ID: 10098759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single center experience with bone marrow transplantation for high risk neuroblastoma.
    Ladenstein R; Lasset C; Bouffet E; Brunat-Mentigny M; Biron P; Philip I; Chauvin F; Philip T
    Bone Marrow Transplant; 1991; 7 Suppl 2():93. PubMed ID: 1878741
    [No Abstract]   [Full Text] [Related]  

  • 32. Localized pelvic neuroblastoma: excellent survival and low morbidity with tailored therapy--the 10-year experience of the French Society of Pediatric Oncology.
    Leclair MD; Hartmann O; Heloury Y; Fourcade L; Laprie A; Mechinaud F; Munzer C; Rubie H
    J Clin Oncol; 2004 May; 22(9):1689-95. PubMed ID: 15117991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma: an effective alternating non-cross-resistant regimen?
    Bernard JL; Philip T; Zucker JM; Frappaz D; Robert A; Margueritte G; Boilletot A; Philippe N; Lutz P; Roche H
    J Clin Oncol; 1987 Dec; 5(12):1952-9. PubMed ID: 3681378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose rapid schedule chemotherapy for disseminated neuroblastoma.
    Pearson AD; Craft AW; Pinkerton CR; Meller ST; Reid MM
    Eur J Cancer; 1992; 28A(10):1654-9. PubMed ID: 1389481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single or double consolidation treatment according to remission status after initial therapy in metastatic neuroblastoma: first results of LMCE 3 study in 40 patients.
    Zucker JM; Philip T; Bernard JL; Michon J; Bouffet E; Gentet JC; Lopez M; Coze C; Philip I
    Bone Marrow Transplant; 1991; 7 Suppl 2():91. PubMed ID: 1878739
    [No Abstract]   [Full Text] [Related]  

  • 36. Toxicity of single-day high-dose vincristine, melphalan, etoposide and carboplatin consolidation with autologous bone marrow rescue in advanced neuroblastoma.
    Gordon SJ; Pearson AD; Reid MM; Craft AW
    Eur J Cancer; 1992; 28A(8-9):1319-23. PubMed ID: 1515242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.
    De Bernardi B; Nicolas B; Boni L; Indolfi P; Carli M; Cordero Di Montezemolo L; Donfrancesco A; Pession A; Provenzi M; di Cataldo A; Rizzo A; Tonini GP; Dallorso S; Conte M; Gambini C; Garaventa A; Bonetti F; Zanazzo A; D'Angelo P; Bruzzi P;
    J Clin Oncol; 2003 Apr; 21(8):1592-601. PubMed ID: 12697885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
    Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
    J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
    Kushner BH; Kramer K; LaQuaglia MP; Modak S; Yataghene K; Cheung NK
    J Clin Oncol; 2004 Dec; 22(24):4888-92. PubMed ID: 15611504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
    Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.